InvaGen Pharmaceuticals is the US oral solids and specialty manufacturing subsidiary of global pharmaceutical company Cipla Limited, operating facilities in Central Islip and Hauppauge, New York to manufacture generic prescription pharmaceuticals and complex formulations.
Cipla US subsidiary InvaGen Pharmaceuticals filed New York WARN Act notices to eliminate 205 manufacturing and operations positions across two Long Island facilities—cutting 160 of 408 workers in Central Islip and 45 of 96 workers in Hauppauge—as part of a corporate cost-optimization and portfolio realignment toward complex generics.
Cipla US subsidiary InvaGen Pharmaceuticals filed New York WARN Act notices to eliminate 205 manufacturing and operations positions across its Central Islip and Hauppauge facilities on Long Island as part of a plant restructuring and portfolio realignment toward complex generics.
Managing Director and Global CEO (Cipla)
No active job listings. Check back later.